Thermo Fisher Scientific Inc. plans to raise €4.4 billion and $900 million from two separate senior notes placements in Europe and the U.S.
The Waltham, Mass.-based company will offer $900 million aggregate principal amount of its 2.6% senior notes due 2029 in the U.S. offering, which will close Oct. 8.
For the Europe offering, the company will issue €800 million aggregate principal amount of its 0.125% senior notes due 2025; €800 million aggregate principal amount of its 0.500% senior notes due 2028; €900 million aggregate principal amount of its 0.875% senior notes due 2031; €900 million aggregate principal amount of its 1.5% senior notes due 2039; and €1 billion aggregate principal amount of its 1.875% senior notes due 2049. The Europe offering is expected to close around Sept. 30.
The company intends to use the proceeds to fund the redemption of the principal amount of several outstanding senior notes.
Goldman Sachs & Co. LLC, Merrill Lynch International, Citigroup Global Markets Ltd. and J.P. Morgan Securities PLC were the joint book-running managers for the Europe offering. The joint book-running managers for the U.S. offering were Goldman Sachs & Co. LLC, BofA Securities Inc., Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc.
